BA.5 Makes Up 80% New Covid Cases

|


According to the recent data from the US Centers for Disease Control and Prevention (CDC), BA.5 Omicron subvariant comprises nearly 80% of the new infections in the US. According to a report, more people are getting infected second or third time.

President Biden, 79, on Thursday announced that he had tested positive for COVID-19 for the first time. He is fully vaccinated with two additional booster doses, The Hill writes.

CNN writesHelix, which sequences Covid-19 tests to monitor variants, recently plumbed its data to find out how many times the same person tested positive for Covid-19 and whether there are more reinfections now compared to earlier waves. Out of nearly 300,000 infections since March 2021, the share that are reinfections almost doubled from 3.6% during the BA.2 wave in May to 6.4% during the BA.5 wave in July.”

Shishi Luo, associate director of bioinformatics and infectious disease at Helix told CNN “The most recent data we had pulled showed that the fraction of all infections that are reinfections have increased quite a bit. There was a jump. She thinks a mix of factors – including waning immunity, broad spread and mutations to BA.5 that help it sneak past the body’s defenses – are probably all contributing to the increase.”

“Statistically speaking, you’re more likely to get reinfected the longer it has been since your last infection, just based on the data we’ve generated,” Luo added.

Laith Abu-Raddad, an epidemiologist with Weill-Cornell Medicine-Qatar, in Doha, Qatar, told CNN “Those who got infected with a pre-Omicron variant now have really limited protection against the infection of BA.4 or BA.5, so they cannot really count on natural immunity to protect them. Those who get infected more recently with an Omicron variant, they have pretty good strong immunity – but of course not total immunity – against reinfection.”

Dr Anthony Fauci, President Biden’s chief medical adviser, said earlier this week “It’s essential that we get more resources, or we’re not going to meet the challenge that’s inevitable. We need the next generation of vaccines, particularly mucosally administered vaccines that would do much better.”